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Abstract
Nerve cell death is the central feature of the human neurodegenerative diseases. It has long been thought that nerve cell
death in these disorders occurs by way of necrosis, a process characterized by massive transmembrane ion currents,
compromise of mitochondrial ATP production, and the formation of high levels of reactive oxygen species combining to
induce rapid disruption of organelles, cell swelling, and plasma membrane rupture with a secondary inflammatory response.
Nuclear DNA is relatively preserved. Recent evidence now indicates that the process of apoptosis rather than necrosis
primarily contributes to nerve cell death in neurodegeneration. This has opened up new avenues for understanding the
pathogenesis of neurodegeneration and may lead to new and more effective therapeutic approaches to these
diseases. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Morphological picture of apoptosis
In the 1960s, Kerr used newly developed lysosomal
staining techniques to reveal a subpopulation of cells
in the ischemic liver that were shrunken and retained
intact lysosomal structure [1]. These cells contrasted
with necrotic hepatic cells that were swollen and had
dissolution of lysosomal organelles. He termed the
process ‘shrinkage necrosis’. Electron microscopy re-
vealed that the shrunken cells had undergone marked
cytoplasmic condensation with budding of condensed
cytoplasm into membrane bound cell fragments,
which were phagocytosed by neighboring cells. Im-
portantly, organelle structure was maintained within
the cell fragments [2]. Prednisone was subsequently
shown to induce shrinkage necrosis in the adrenal
cortex and adrenocorticotropic hormone was shown
to prevent prednisone-induced shrinkage necrosis [3].
In 1972, Kerr et al. [4] described the ultrastructural
features of shrinkage necrosis and termed the process
‘apoptosis’. They noted that the nuclei showed chro-
matin condensation and segregated into sharply de-
lineated masses that abutted on the inner nuclear
membrane. The plasma membrane remained intact,
but underwent marked blebbing. The condensed cy-
toplasm was fragmented into membrane-wrapped
bodies that were engulfed by macrophages without
an apparent in£ammatory reaction. Finally, apop-
totic bodies were described that contained either nu-
clear or cytoplasmic material, or both. The morpho-
logical picture of apoptosis described by Kerr et al.
remains the standard today. Cytoplasmic and nu-
clear changes shown by electron microscopy provide
the best evidence that cells have entered the late
stages of apoptosis. The picture is slightly di¡erent
in vitro where, in the absence of macrophages, apop-
totic bodies persist for a longer period of time and
may undergo cytolysis or secondary necrosis.
2. Nerve cell apoptosis
As early as 1951, it was known that nerve cell
death played a major role in vertebrate embryogen-
esis [5]. It is now known that a massive death of
neurons occurs during vertebrate prenatal and post-
natal brain development and that this is related to
failed competition for trophic factors [6] and repre-
sents a form of apoptosis [4]. The neurotrophic hy-
pothesis proposed that nerve cells depend on trophic
support from their targets for survival, and that the
targets could only supply limited amounts of trophic
molecules so that developing neurons were forced to
compete for trophic support [7]. Elegant experiments
showed that the neurons with ‘the best connections’
survived and maintained their connections, while
weakly connected neurons died [8]. The death proc-
ess in these developing neurons was termed ‘pro-
grammed cell death’ since it was shown to depend
on activation of an intrinsic program of gene expres-
sion that led to self destruction though the synthesis
of ‘death proteins’ [9]. The dependence on new pro-
tein synthesis was similar to that found in the apop-
tosis that occurs in cultured sympathetoblasts de-
prived of NGF [10]. It has subsequently become
clear that new protein synthesis is not necessary for
all forms of neuronal apoptosis [11,12]. In some
forms of neuronal apoptosis, proteins that are neces-
sary for apoptosis to occur are constitutively ex-
pressed, while they must be newly synthesized in
others [13,14]. The characteristic morphologic ¢nd-
ings of apoptosis persist in some models of nerve
cell apoptosis, even when transcriptional and trans-
lational blockers are used to inhibit new protein syn-
thesis. For example, transcriptional or translational
blockers that greatly reduce new protein synthesis do
not prevent apoptosis after serum withdrawal in
PC12 cells that have been exposed to serum, but
not to NGF [15]. Similarly, PC12 cells that have
been exposed to NGF for 6 days and have initiated
process growth, undergo apoptosis after serum and
NGF withdrawal that is independent of new protein
synthesis [16]. In contrast, apoptosis in neuronally
di¡erentiated PC12 cells caused by trophic with-
drawal after 9^12 days of NGF exposure requires
new protein synthesis [17]. Therefore, apoptosis can
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be dependent on new protein synthesis and termed
programmed cell death, or can be independent
of new protein synthesis and be unprogrammed.
Indeed, in some cases nerve cell apoptosis can be
facilitated by the inhibition of new protein synthesis
[18], likely due to loss of protection provided
by newly synthesized anti-apoptotic proteins.
Thus, dependence on new protein synthesis
can be used as a marker for neuronal apoptosis
[19,20], but its absence does not rule out apoptosis
[21].
In developing neurons, apoptosis was thought to
provide a counter balance for overexuberant cell rep-
lication. It therefore seemed unlikely to involve adult
nerve cells, since they are unable to replicate. It is
now appreciated that nerve cell apoptosis can occur
in response to a variety of insults, many of which are
relevant to the pathogenesis of human neurodegener-
ative diseases. For example, neuronal apoptosis can
be caused by exposure to excitatory amino acids
[22,23], the parkinsonian toxin MPTP [24] and its
metabolite, MPP [25^27], 6-hydroxydopamine [28],
the 25^35 fragment of L-amyloid protein [29,30], mu-
tated presenilin 2 [31], mitochondrial complex I in-
hibitors [32], pro-oxidants, like H2O2 [33], iron [34],
cycad £our [35], high levels of dopamine [36] or lev-
odopa [37], the AIDS protein gp120 [38], and over-
expression of the mutant superoxide dismutase (sod-
1) gene from patients with familial amyotrophic lat-
eral sclerosis (ALS) [39].
In general, lower concentrations of toxins, partic-
ularly if delivered over a more protracted time
course, induce apoptosis while higher levels induce
necrosis [23]. For example, high concentrations of
the L-amyloid protein fragment induce necrosis
[40], while smaller concentrations cause apoptosis
[29,41,42]. Intermediate concentrations often induce
a mixture of necrosis and apoptosis, with the necrosis
occurring in the ¢rst few hours after exposure and
apoptosis appearing after a number of hours or days.
Despite the demonstration that apoptosis is an im-
portant form of nerve cell death, it did not receive
recognition as a key factor in neuronal degeneration
until the present decade. Part of the reason for this
stems from the di⁄culty in demonstrating apoptotic
cells because of their relatively short existence. In
vivo, apoptotic nuclei and bodies are phagocytized
and digested within a matter of hours. Thus, only a
small number of apoptotic nuclei may be seen at one
time, which creates the impression that apoptosis
plays an inconsequential role. Yet, the presence of
a small number of apoptotic nuclei in a tissue section
at single point in time may re£ect large numbers of
apoptotic deaths if the process is ongoing over a
period of days, weeks, or years [43]. Accordingly,
in the chronic neurodegenerative diseases, massive
apoptotic death may occur even though only a small
number of apoptotic pro¢les can be seen in a single
pathological specimen.
Another limitation has been the development of
markers that can be used to detect apoptosis in tissue
sections. In 1980, Wyllie reported that endogenous
endonuclease activation in apoptosis resulted in nu-
clear DNA fragmentation [44]. Agarose gel electro-
phoresis demonstrated a 180^200 bp ‘ladder’ pattern
of DNA degradation typical of internucleosomal
DNA cleavage. DNA fragments of 300 or 500 bp
in length are also formed and can be better detected
with pulse ¢eld techniques [45,46]. The presence of
endonuclease-mediated DNA cleavage provides con-
clusive evidence of apoptosis. However, large
amounts of tissue are required to detect DNA cleav-
age with these techniques, so they are not suitable for
detecting small numbers of apoptotic nuclei in a
post-mortem brain. Nuclear DNA cleavage can be
more readily detected using in situ end labeling
(ISEL) techniques which attach a chromagen or £u-
orochrome to the 3P cut ends of DNA [47,48]. Chro-
matin condensation can also be used as a measure of
apoptosis. It ensues as a result of DNA fragmenta-
tion and can be detected using £ow cytometry [49] or
in situ staining with £uorescent DNA binding dyes,
such as acridine orange or YOYO-1 [6,50]. The ISEL
techniques have been widely used to detect apoptosis
in neurodegenerative diseases, but there are concerns
that in situ end labeling methods detect nuclear
events other than those associated with apoptosis
and that maintenance of human brain tissue in ¢x-
atives or tissue drying can induce false-positives and
false-negatives [51^54]. Positive staining of individual
neurons with both an ISEL technique and a dye that
marks chromatin condensation has been proposed to
unambiguously establish the presence of apoptosis
[55,56].
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3. Changes in gene expression and protein levels in
apoptosis
In recent years, a number of genes and their pro-
tein products have been uncovered, which can in£u-
ence or determine the progression of apoptosis and
serve as markers of the process. Furthermore, a num-
ber of cytoplasmic proteins undergo nuclear trans-
location and mark the early stages of apoptosis. On-
coproteins, anti-oncogenes, and several protease
families have received particular attention as media-
tors or modi¢ers of apoptosis. The BCL-2 homolog
family of oncoproteins includes both inhibitors and
promoters of apoptosis [57]. Inhibitors of apoptosis
include BCL-2 itself, BCL-X (BCL-XL, BCL-XK,
and BCL-XL), MCL-1, and A1, while BAX, BCL-
XS, BAD, BAK, and BIK promote apoptosis. Some
of the BCL-2 family members can also interact with
each other by forming homo- or heterodimers. While
the subcellular location of each of the family mem-
bers di¡ers slightly, most are found in the outer mi-
tochondrial and nuclear membranes. In normal he-
mopoetic cells, BCL-2 is concentrated in the outer
mitochondrial membrane, while BAX is largely con-
¢ned to the cytosol [58], however during apoptosis
BAX becomes concentrated in mitochondrial mem-
branes.
BCL-2, BCL-XL, and BAX are the members of the
BCL-2 family that are most prominently expressed in
mammalian nervous tissue. In rodents, BCL-2 levels
are high in the immature central nervous system, but
decline in the adult nervous system. Small but detect-
able levels of BCL-2 mRNA and protein are found
in neurons in a number of structures in the adult
human brain, including the cerebral cortex, basal
ganglia, basal nucleus of Meynert, substantia nigra,
and cerebellum [59]. In contrast to neurons in the
central nervous system, BCL-2 levels remain high
in many adult peripheral neurons and can also be
detected in microglial cells. BCL-XL is almost en-
tirely neuronal and remains high in many adult neu-
rons. BAX is also expressed in some adult neurons.
Although BCL-2, BCL-XL and BAX have been
shown to be capable of altering the progression of
apoptosis [60] and appear to contribute to neuronal
selection during embryonic and postnatal develop-
ment [57], relatively little is known about the roles
of these oncoproteins in the mature nervous system.
BCL-2 and BCL-XL decrease while BAX and BCL-
XS increase in neurons entering apoptosis in vivo
[61^65]. In tissue culture, we have found that pri-
mary neurons or neuron-like cells show decreases
in BCL-2 and BCL-XL in the early stages of apop-
tosis induced by trophic withdrawal, pro-oxidants, or
mitochondrial respiratory chain inhibitors. BCL-2
and BCL-XL levels are increased in neurons follow-
ing low level damage which is insu⁄cient to induce
apoptosis. These cells are subsequently resistant to
damage that normally would induce apoptosis.
BCL-2 is also increased in the human nervous system
in a variety of circumstances where neurons may
have undergone damage, but have not yet entered
into the apoptotic process. In contrast, BAX levels
are increased in neurons that have sustained damage
and are committed to undergo apoptosis. Accord-
ingly, increased BCL-2 levels may re£ect the induc-
tion of a survival program in neurons that have sus-
tained damage that is not su⁄cient to cause
apoptosis, while increased BAX levels may mean
that the neuron has progressed to the early stages
of apoptosis.
A number of proteases, including cysteine pro-
teases, calpains, and proteasomes have been shown
to contribute to apoptosis. Most attention has fo-
cused on the interleukin converting enzyme (ICE)-
like proteases which are termed caspases, the c de-
noting cysteine protease and the aspase referring to
the tendency of the enzymes to cleave after an as-
partic acid residue [66,67]. To date, 10 di¡erent cas-
pases have been identi¢ed and named caspases 1^10.
The caspases are synthesized as inactive precursors.
Several of the caspases, particularly caspase 3, have
been shown to be activated in models of neuronal
apoptosis [68^72]. Speci¢c calpains have been shown
to contribute to the cleavage of the cytoskeletal pro-
tein actin that occurs during apoptosis [73,74] and
calpain inhibitors block actin cleavage in apoptosis
[75].
A number of cell-cycle related proteins and cycle
kinases increase in nerve cell apoptosis including cy-
clin D1, cyclin B, cyclin E, and Cdc2 kinase [76^82].
It has been proposed that the appearance of the
cycle-related proteins represents an abortive attempt
of the post-mitotic cells to return to the cell cycle
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[83]. In this regard, the mitosis inhibitor protein,
p53, increases in a number of forms of neuronal
apoptosis [84,85] and has been shown to increase
BAX levels in non-neuronal forms of apoptosis
[86,87].
Apoptosis can be separated into p53-dependent
and p53-independent forms (see [88] for a detailed
review of the role of p53 in apoptosis). Recently, a
large number of p53-induced genes or PIGs have
been uncovered, which are proposed to mediate
apoptosis by increasing reactive oxygen species
(ROS) levels, thereby inducing mitochondrial dam-
age [89]. p53-induced apoptosis can proceed after
treatment with translational or transcriptional block-
ers [90,91], indicating that p53 can induce apoptosis
through pathways that do not require new protein
synthesis [92].
c-JUN, a signal-transducing transcription factor
of the AP-1 family, is normally involved in cell
cycle control, di¡erentiation, and cell transforma-
tion. A variety of evidence indicates that c-JUN is
involved in the induction of some forms of apoptosis
[93,94], and that it is increased in a number of in
vitro and in vivo models of neuronal apoptosis
[30,95^99].
Another marker for apoptosis is tissue transgluta-
minase, which cross-links cytoplasmic proteins and is
increased in apoptotic cells and apoptotic bodies
[100]. Transglutaminase activity leads to the forma-
tion of high molecular mass protein polymers, which
maintain the integrity of apoptotic cells and bodies
and prevents leakage of their contents into the ex-
tracellular space. Fas antigen induces apoptosis that
is BCL-2 independent (see [101] for a review of apop-
tosis mediation by Fas antigen) and its mRNA in-
creases in ischemic nerve and glial cells [102]. Lastly,
the gene for the radical scavenger protein, Cu/Zn
superoxide dismutase (SOD-1), reduces neuronal
apoptosis when over expressed [103,104] and in-
creases apoptosis when under expressed [105].
Chronic inhibition of SOD1 causes spinal moto-
neurons to die by apoptosis [106]. Point mutations
in the gene that encodes SOD-1 have been detected
in patients with familial ALS [107]. In cultured
neurons, these point mutations convert the anti-
apoptotic action of SOD-1 to a pro-apoptotic one
[39].
4. Evidence for apoptosis in neurodegenerative
diseases
In recent years, apoptosis has been described in a
variety of human neurodegenerative disorders, pri-
marily based on the use of ISEL techniques to detect
neuronal nuclei with apparent DNA cleavage in
post-mortem brain tissue. ISEL-positive nuclei have
been reported in brains or spinal cords of patients
with Parkinson’s disease (PD) [56,108^110], Alzheim-
er’s disease (AD) [111^114], Huntington’s disease
(HD) [111,115], and ALS [115,116]. Some investiga-
tors have failed to ¢nd evidence of nuclear DNA
strand breaks in some of the above conditions [52]
and have challenged the reliability of ISEL techni-
ques as a marker of apoptosis in postmortem tissue
[53,54]. More de¢nitive evidence in support of apop-
tosis are the electron microscopic ¢ndings of nuclear
chromatin condensation in the substantia nigra pars
compacta (SNc) of PD brains [117]. Changes were
only detected in the SNc and were not seen in normal
controls. In addition, we have studied PD postmor-
tem brains with both an ISEL technique and the dye
YOYO-1 that stains for chromatin condensation
[56]. Approximately 1^2% of individual melanin-con-
taining neurons in the SNc of PD patients stained
positively with both of these techniques compared to
only 0.2% in age-matched controls. Positive staining
of a single neuron with both of these techniques
avoids the risk of false-positive results that may oc-
cur with either one and we believe establishes the
presence of apoptosis.
Another concern that has been raised is the rela-
tively high percentage of nuclei that have DNA
strand breaks in AD [118] and PD [56,109,110,117]
brains using the ISEL techniques. In one study of
neuronal apoptosis in the SNc of mice exposed to
MPTP, about 45% of neurons died over a period
of about 10 days. Nonetheless, an average of less
than 1% percent of dopaminergic neurons showed
ISEL and chromatin condensation positive nuclei at
any one time during this period (maximum of 4^6%)
[55]. The death of murine nigral neurons after MPTP
exposure occurs synchronously over a short period
of time [119] while the death of nigral neurons in PD
likely occurs asynchronously over many years. Ac-
cordingly, the percentage of nigral ISEL-positive nu-
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clei found in PD and AD brains seems high, even if
some ISEL-positive nuclei are glia.
However, the large number of apoptotic cells that
have been detected in the brains of patients with
neurodegenerative disorders might re£ect accelerated
apoptosis as a result of agonal events in neurons that
were pre-apoptotic and committed to undergo apop-
tosis at a later time point. Degenerating nerve cells
may be in a pre-apoptotic state for some time before
entering the end stages of apoptosis as marked by
chromatin condensation and DNA cleavage.
Changes in tissue perfusion and oxygen levels in
the period prior to death may accelerate the entry
of these cells into the ¢nal stages of apoptosis.
Such a mechanism might explain the higher than
expected levels of ISEL-positive nuclei and the fact
that the nuclei are only found in brain regions
known to be a¡ected by the speci¢c neurodegenera-
tive disease.
In support of this concept are changes in apopto-
sis-related gene expression and protein levels in the
same structures, and in some cases in the same neu-
rons, in which nuclear DNA cleavage are found.
BCL-2 was found to be decreased in neurons of
AD patients with neuro¢brillary tangles, but was in-
creased or unchanged in nearby una¡ected neurons
[59]. Similarly, increased BCL-2 expression was
noted in surviving SNc neurons in PD brains [120].
In AD postmortem brains, increased c-JUN immu-
noreactivity has been detected [118,121]. Staining
was observed in nerve cells with ISEL-positive nuclei
as well as in some nerve cells without ISEL-positive
nuclei, suggesting that these nerve cells may have
entered the early stages of the apoptotic process
but had not yet progressed to the point of nuclear
DNA cleavage. Indeed, there is evidence of increased
BAX expression in dopamine neurons that have not
yet undergone nuclear DNA cleavage following ex-
posure to MPTP [61]. This may suggest that these
cells were heading toward apoptotic death at the
time of sacri¢ce. The ¢nding of neurons in AD
brains with increased levels of BAX and c-JUN,
but without evidence of nuclear DNA cleavage, sup-
ports the existence of pre-apoptotic neurons in neu-
rodegenerative diseases. Other gene and protein
changes that have been found in the post-mortem
brains in neurodegenerative diseases and that sup-
port the notion that apoptosis has occurred include
increased transglutaminase [122] and BAX [123], the
appearance of cyclin B, cyclin E, Cdc2 kinase [124],
and the cyclin-dependent kinase inhibitor p16 [125],
and an increase in p53 in cortical astrocytes [126].
BAX is also heavily concentrated in senile plaques
and neuro¢brillary tangles [121] and FAS antigen
has been found in senile plaques in AD[127] and in
the SNc in PD [128]. Lastly, apoptosis-like actin
cleavage has been demonstrated in neurons associ-
ated with senile plaques in AD brains [129,130].
It is also possible that agonal events induce apop-
tosis to occur in vulnerable neurons that otherwise
would not have entered apoptosis at that time. We
have recently noted that mitochondrial membrane
potential is reduced in ¢broblasts derived from
some PD patients (discussed below). If a decrease
in mitochondrial membrane potential is also present
in SNc neurons in PD, they may be vulnerable and
prone to enter apoptosis under conditions in which
normal neurons would survive. Thus, the relatively
high percentages of ISEL-positive nuclei in PD and
AD brains may be due to accelerated DNA cleavage
in nerve cells that were already committed to under-
go apoptosis at a later date or that were vulnerable
to the apoptotic process.
Taken together, the evidence for nuclear changes
typical of apoptosis and the ¢nding of changes in the
expression of apoptosis-related genes and their pro-
tein products makes it highly likely that apoptosis
contributes to nerve cell loss in human neurodegener-
ative diseases.
5. The role of mitochondria in some forms of
apoptosis
5.1. Mitochondrial defects and neurodegenerative
diseases
Defects in mitochondrial energy metabolism have
been proposed to underlie neurodegenerative diseases
[131,132]. Toxins that damage the mitochondrial res-
piratory complexes induce de¢cits in animals that are
very similar to those found in speci¢c human neuro-
degenerative diseases. MPTP and 3-nitropropionic
acid poison complexes I and II, respectively, and in-
duce neurological de¢cits in monkeys that are very
similar to PD and HD [133]. Agents, like coenzyme
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Q10 and nicotinamide, that improve electron transfer
in the respiratory chain, reduce parkinsonian-like
de¢cits in MPTP monkeys [134]. Complex I activity
is decreased in the SNc of PD postmortem brain
tissue [135,136] while complexes II, III, and IV activ-
ity are reduced in a¡ected regions of AD brains
[137]. A decrease in cytochrome oxidase activity ap-
pears to be part of the AD complex IV de¢cit
[138,139]. Decreases in the mRNAs for subunits I
and III of cytochrome oxidase have been reported
in the association cortex of AD brains [140]. De-
creases in complex II and III activity have been
found in the caudate nucleus in HD [141]. A complex
I defect has been found in platelets and leukocytes
from PD patients [142] and a decrease in cytochrome
oxidase has been reported in platelets from AD pa-
tients [143]. Other studies suggest that there is also
decreased complex I activity in PD ¢broblasts [144].
Studies using cybrids have shown that the decreased
complex I activity in PD platelets and the cyto-
chrome oxidase defect in AD platelets can be trans-
ferred to multiple generations of recipient cells
[145,146], indicating that activity decreases are intrin-
sic to the mitochondrial genome in PD and AD.
It has been proposed that defects in the mitochon-
drial respiratory chain could cause neuronal degen-
eration through decreased ATP formation or in-
creased production of ROS [132,146,147]. Decreases
in mitochondrial membrane £uidity in mitochondria
from AD brain tissue [148] and increases in protein
adducts of lipid peroxidation in PD brain tissue [149]
have been interpreted as resulting from ROS-medi-
ated membrane peroxidation. According to that
view, cell death in neurodegenerative diseases could
result directly from mitochondrially generated ROS.
Recent studies support another means by which
mitochondrial dysfunction may induce neuronal
death, namely, apoptosis. Mitochondria are now be-
lieved to play a critical role in signaling for the ini-
tiation of some forms of apoptosis. Apoptosis was
initially believed to occur independently of mito-
chondrial factors [150,151]. The importance of mito-
chondria in the initiation of apoptosis is illustrated
by the ¢nding that mitochondrial factors can induce
chromatin condensation and nuclear fragmentation
typical of apoptosis in cell free Xenopus egg extracts
[152]. Current evidence now indicates that apoptosis
is associated with a sequence of events that includes
a fall in mitochondrial membrane potential (v8M),
opening of a mitochondrial megapore known as the
permeability transition pore (PTP), and release into
the cytoplasm of small mitochondrial proteins which
signal for the initiation of apoptosis known as apop-
tosis-initiating factors (AIF). This changing view
o¡ers new ways of interpreting the evidence for
mitochondrial respiratory chain dysfunction in
neurodegenerative diseases and may also o¡er new
therapeutic targets for the treatment of neurodege-
nerative disease. The schema is discussed in detail in
the following sections.
5.2. Mitochondrial membrane potential and apoptosis
Studies of the mitochondrial membrane potential
(v8M) have been pivotal in understanding the rela-
tionship between mitochondria and the initiation of
apoptosis. An electrochemical proton gradient nor-
mally exists across the inner mitochondrial mem-
brane resulting in a v8M of approximately 3150
mV and a proton concentration di¡erence (vpH)
across the mitochondrial membrane. The v8M is de-
pendent on the capacity of mitochondrial complexes
I, III, and IV to use electron energy in the carrier
molecules nicotinamide adenine dinucleotide
(NADH), ubiquinone, and cytochrome c (CytC) to
pump protons out of the mitochondrial matrix by
transporting them across the inner mitochondrial
membrane. Complex II transfers energy from
FADH2 to ubiquinone, but does not pump protons.
The outward pumping of protons produces an elec-
tron gradient that is biochemically re£ected by a pH
di¡erence (vpH) and electrically by a voltage across
the inner mitochondrial membrane termed the mito-
chondrial membrane potential (v8M) [153]. The
v8M and the vpH contribute to a proton electro-
motive force (Np) (Np =v8M360 vpH) where
vpH = mitochondrial pH3cytosol pH. Np drives the
conversion of ADP to ATP at complex V (ATP syn-
thase). Since v8M is by far the greatest contributor
to Np, in most instances it can be assumed that v8M
varies almost linearly with the ATP/ADP ratio and
provides an estimate of the ATP/ADP ratio within
individual mitochondria.
Measurements of whole cell potentiometric dye
£uorescence in a variety of blood, hepatic, and im-
mune cell models have shown that v8M is reduced
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very early in the apoptotic process, prior to the onset
of nuclear DNA fragmentation and chromatin con-
densation (reviewed in reference [154]). More re-
cently, our group used laser confocal imaging to ob-
tain direct measurements of v8M in living NGF-
di¡erentiated PC12 cells and showed that a decrease
in v8M is also one of the earliest, if not the earliest,
detectable event in apoptosis induced by NGF and
serum withdrawal [155]. v8M was signi¢cantly re-
duced in a proportion of mitochondria 3^6 h prior
to nuclear DNA fragmentation and chromatin con-
densation. The decrease in v8M was temporally cor-
related with an increase in intramitochondrial Ca2,
but not with the increase in cytosolic ROS levels
which occurred only after the decrease in v8M was
well established. Decreases in v8M coupled with in-
creases in intramitochondrial Ca2 induce opening of
the PTP (see below) [156]. Accordingly, changes
found in early apoptosis are appropriate to open
the PTP.
5.3. Permeability transition pore
A decrease in v8M, in the presence of increased
intramitochondrial Ca2 [156], induces opening of a
PTP which spans the inner and outer mitochondrial
membranes. Details on the puri¢cation and the in
vitro reconstitution of the PTP have recently been
provided [157,158]. A schematic diagram illustrating
the components of the PTP is provided in Fig. 1A,
although the precise structure of the PTP is uncertain
[159]. The adenine nucleotide translocator (AdNT) is
a critical element of the PTP, but whether it forms
the pore itself or is just closely associated with a
Fig. 1. Schematic representation of major components of the permeability transition pore and factors or agents which induce pore
opening or pore closing. The major pore components of the PTP are shown in A in a schematic form designed to create a pore. The
components are appropriately localized to the outer membrane, the intermembranous space, and the inner membrane, but their actual,
relationships to each other and how those relationships create a pore spanning the inner and outer membranes are not known. The
box in A de¢nes the component names which have been abbreviated in the schematic and includes symbols for a number of agents
known to in£uence pore opening or closing. A number of other components of the PTP are not shown in the schematic diagram but
are included in the text. In B and C, the putative interactions of speci¢c factors and agents with di¡erent components of the PTP are
schematized to illustrate how these factors or agents might in£uence the probability of opening or closing of the pore. If a reduction
in the v8M and opening of the PTP are factors in neuronal apoptosis in the neurodegenerative diseases, then the agents shown in B
and C, and the mechanisms whereby they in£uence opening or closure of the PTP, may lead to the development of new agents with
the capacity to block apoptosis and slow the progression of the human neurodegenerative disorders.
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pore-forming protein is unknown. The PTP also in-
cludes a voltage-dependent anion channel (a porin)
and a peripheral benzodiazepine receptor (PBR). As
shown in the schematic drawing, these components
are closely associated with hexokinase, creatine ki-
nase, and BCL-2, as well as other elements, such as
glycerol kinase, phospholipid hydroperoxidase, glu-
tathione peroxidase, 3-b-hydroxysteroid dehydrogen-
ase isomerase, and cardiolipin synthase, which are
not shown in the diagram.
The PTP opens in response to a decrease in v8M
in the presence of an increase in intramitochondrial
Ca2 [160]. Marked increases in mitochondrial Ca2,
increased oxidative radical levels, or partial failure of
the respiratory complexes, acting either individually
or together, can induce a fall in v8M [161]. Opening
of the PTP dissipates any remaining proton gradient
across the mitochondrial membrane and further re-
duces the v8M [162]. Opening of the PTP could itself
theoretically induce apoptosis, but it is more likely to
lower threshold than to initiate apoptosis [160,162].
Complete opening of the PTP allows free exchange
between the mitochondrial matrix and the extrami-
tochondrial cytosol of solutes and proteins smaller
Fig. 1 (continued).
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than 1500 Da [163]. This can result in mitochondrial
swelling and rupture of the outer mitochondrial
membrane with the release of heat labile AIFs such
as cytochrome c from the intermembrane space of
the mitochondria into the cytoplasm [164^167].
While intermembrane AIFs such as cytochrome c
do not transit through the PTP [168], they can be
released into the cytoplasm through fractures in the
mitochondrial membrane. Glutathione is actively
concentrated in the mitochondrial matrix and release
of glutathione from mitochondria is considered to be
a de¢nitive marker of PTP opening [169].
Several factors are known to in£uence opening or
closure of the PTP. Elements that favor pore closing
are anti-apoptotic and are illustrated in Fig. 1B.
Those that favor pore opening promote apoptosis
and are shown in Fig. 1C. Cyclosporin A binds to
the PTP and maintains it in a closed position. It also
promotes pore closure by binding cyclophilins that
otherwise induce PTP opening in the presence of
Ca2 by binding to the AdNT [160,162]. Factors
like glutathione, ADP levels, and ROS levels in the
mitochondrial matrix modulate the gating voltages
necessary to induce PTP opening but are not su⁄-
cient in themselves to open the PTP [170]. The anti-
apoptotic protein BCL-2 maintains closure of the
PTP in a manner similar to cyclosporin A. Recently,
it has been found that the levels of expression of
BCL-2 and the PBR correlate in lymphoid cell lines
and that BCL-2 co-immunoprecipitates with the
PBR [171]. These ¢ndings indicate that BCL-2 likely
binds to the PBR component of the mitochondrial
PTP. BCL-2 has been shown to localize to the outer
mitochondrial membrane [172^175] within, or near
to, the mitochondrial PBR [171]. Truncated BCL-2,
which cannot dock in mitochondrial membranes and
remains in the cytosol, is considerably less e¡ective in
reducing apoptosis than BCL-2 located in mitochon-
drial membranes [176]. Richter ¢rst proposed that
BCL-2 reduces apoptosis by maintaining v8M
[161]. Zamzami and coworkers subsequently pro-
vided persuasive evidence for this concept, demon-
strating that BCL-2 maintains PTP closure [177]
and blocks the initiation of apoptosis by preventing
the escape of heat labile molecules which signal for
the onset of apoptosis. Numerous other studies have
also shown that BCL-2 can prevent a decrease in
v8M and the release of ICE-like AIFs
[164,166,167]. BCL3XL similarly regulates v8M
and matrix volume within mitochondria [178].
Thus, opening of the PTP is a critical step in many
forms of apoptosis and is proposed to constitute an
irreversible step in the process [179].
5.4. Apoptosis-initiating factors
The importance of mitochondrial factors in the
initiation of apoptosis is demonstrated by the ¢nding
that mitochondrial homogenates are essential for the
progression of the nuclear changes of apoptosis in
cell free systems [152]. Several mitochondrial AIFs,
which promote apoptosis, have been identi¢ed to
Fig. 2. Relationship of cytochrome c immunodensity to v8M and DNA fragmentation. Simultaneous images of v8M using the £uoro-
chrome CMTMR (Molecular Probes, Oregon), CytC immunodensity, and YOYO-1 DNA binding in PC12 cells that had been ex-
posed to serum and NGF for 6 days (see [155] for details). A1, A2, and A3 show identical image ¢elds for a normal appearing, neu-
ronally di¡erentiated PC12 cell that was washed and then replaced in serum and NGF 6 h previously. B1, B2, and B3 show identical
image ¢elds for four PC12 cells that were washed and then placed in minimum essential media 6 h previously. Placement in minimum
essential media without NGF or serum has induced apoptosis in one of the neuronally di¡erentiated PC12 cells (see arrow), with nu-
clear chromatin condensation and DNA cleavage appearing between 6 and 12 h. A1 and B1 show binary addition of the images for
DNA (green color) and v8M (red color). The upper cell in B1 (arrow) shows a nucleus with typical DNA condensation into apoptotic
bodies, while the cell in A1 and the lower three cells in B1 show normal intranuclear DNA organization. Note that the apoptotic cells
with nuclear DNA condensation (arrow) shows a marked reduction in v8M, as revealed by the decrease in red intensity. A2 and B2
show binary addition of the images for cytC immunodensity (green color) and v8M (red color). The cell in A2 shows that most of
the CytC is co-localized with v8M as revealed by the yellow and orange coloration resulting from red^green addition. The lower three
cells in B2 show less bright yellow coloration in accordance with lower intramitochondrial CytC immunodensity. The apoptotic cell in
B2 also shows increased cytoplasmic CytC immunodensity that has been shown to be extramitochondrial by co-staining for intramito-
chondrial biotin (not shown). A3 and B3 show binary addition of the images for cytC immunodensity (green color) and DNA (red
color). A3 shows the typical discrete localization of CytC immunodensity in trophically supported cells, while B3 shows the more
globular appearance of cytoplasmic CytC found in apoptotic or pre-apoptotic cells.
C
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date. dATP, when accompanied by holocytochrome
c, a nuclearly encoded 14 kDa protein which is nor-
mally localized to the mitochondrial intermembra-
nous space, can promote the nuclear DNA changes
of apoptosis in some cell free systems [180]. Addi-
tionally, in some forms of apoptosis, CytC can be
found in the extramitochondrial cytosol in the early
stages of apoptosis [181] and injection of CytC into
cells induces apoptosis [182]. CytC release from mi-
tochondria has been shown to activate a caspase 3
precursor leading to activation of an endonuclease
that cleaves nuclear DNA [181,183,184]. On the oth-
er hand, the anti-apoptotic agent BCL-2 has been
shown to block the release of CytC from mitochon-
dria [181].
It has been reported that an increase in cytosolic
holocytochrome c occurred prior to any decrease in
v8M [185]. This ¢nding is inconsistent with other
work showing that opening of the PTP caused by a
fall in v8M results in the escape of CytC from mi-
tochondria [186,187]. The assertion that cytosolic
CytC increases independently of v8M is uncertain
since the measurement of v8M in this study em-
ployed DiOC6(3) in whole cells [185]. DiOC6(3) has
a relatively low sensitivity to gradations in v8M
[188]. It may be unsuitable for quantitative studies
as whole cell measurements of v8M can neglect
marked decreases in v8M in a subpopulations of
mitochondria within individual cells (see [155] for
details). We have examined apoptosis in partially
neuronally di¡erentiated PC12 cells induced by
NGF and serum withdrawal and have simultane-
ously imaged CytC and v8M immunodensity in in-
dividual mitochondria and in the neighboring cyto-
plasm (Rideout, Chalmers-Redman, Pong and
Tatton, unpublished observations). At high and me-
dium levels of v8M, mitochondrial CytC content in
these locations varies randomly with v8M. At low
v8M levels, intramitochondrial CytC levels fall dra-
matically and nearby cytoplasmic CytC levels in-
crease reciprocally (see illustrations of increases in
extramitochondrial CytC immunodensity in pre-
apoptotic and apoptotic cells in Fig. 2). Importantly,
we found that losses of v8M in a relatively small
subpopulation of a cell’s mitochondria can notice-
ably increase CytC immunodensity in the cytoplasm.
Although another study of apoptosis failed to ¢nd a
decrease in modal levels of v8M prior to increases in
levels of cytosolic CytC [189], examination of the
distributions of v8M for the whole mitochondrial
population reveals a subpopulation of mitochondria
whose v8M loss correlates temporally with increas-
ing cytosolic CytC levels.
Another mitochondrial AIF has been identi¢ed as
an interleukin converting enzyme-like (ICE) pro-
tease, since it can be inhibited by N-benzyloxycar-
bonyl-Val-Ala-Asp £uoromethylketone, an inhibitor
speci¢c to the ICE family [167]. BCL-2 has also been
shown to prevent the release of this AIF, presumably
by maintaining closure of the PTP and preserving the
v8M [167].
Subcellular translocation of several small cyto-
plasmic proteins have also been seen in association
with apoptosis. Hunot et al. have shown that
stimulation of tumor necrosis factor-K (TNF-K) re-
ceptors on cultured dopamine neurons induces nu-
clear translocation of NFU-B in association with in-
duction of apoptosis [190]. A 70-fold increase in
nuclear translocation of NFU-B has been detected
in neurons in the SNc in PD patients [190]. It re-
mains unclear whether nuclear translocation of
NFU-B promotes cell death or represents an attempt
to upregulate a survival program and protect against
cell death. Glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH), an intermediary enzyme in glycolytic
metabolism and a factor in mRNA translation, has
also been implicated in apoptosis [191,192]. GAPDH
normally exists in the cytoplasm as a tetramer bound
to AU-rich regions of RNA. In some models of
apoptosis, GAPDH has been shown to accumulate
in the nucleus, and to be associated with transcrip-
tional events related to apoptosis. Our preliminary
data indicates that NAD or ROS can displace
GAPDH from cytoplasmic RNA binding sites and
permit it to accumulate in the nucleus (Carlile, Bor-
den, Chalmers-Redman, Fraser and Tatton unpub-
lished ¢ndings). Using size a⁄nity chromatography,
we have shown that the anti-apoptotic molecules
(3)-desmethyldeprenyl (DMS) and CGP 3466 (a tri-
cyclic analog of DMS), which have neuroprotective
bene¢ts in tissue culture models of nerve cell apop-
tosis [193,194] bind to GAPDH and preferentially
maintain it as a dimer, in which form it does not
accumulate in the nucleus and does not promote
apoptosis. Although the precise mechanism whereby
GAPDH contributes to apoptosis is not known, re-
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cent work in our laboratory suggests that nuclear
accumulation of GAPDH is associated with a fall
in levels of BCL-2, and that this reduction is pre-
vented by anti-apoptotic agents such as DMS and
CGP-3466. Preliminary data now indicate the pres-
ence of GAPDH nuclear translocation in the PD
nigra.
It is apparent that there are many di¡erent AIFs
and that di¡erent ones may be operative in di¡erent
models of apoptosis. Studies in multiple myeloma
cells showed that cytosolic CytC levels were in-
creased early in apoptosis induced by ionizing radi-
ation, but not in apoptosis induced by dexametha-
sone or anti-FAS antibody [195]. The apoptosis
induced by ionizing radiation is likely p53-depend-
ent, while the latter two methods of inducing apop-
tosis are p53-independent. Similarly, microinjection
of CytC into human kidney 293 cells induces apop-
tosis while it does not in MCF7 breast carcinoma
cells [182]. It is also clear that a variety of di¡erent
AIFs that are released from mitochondria in re-
sponse to a fall in v8M, and opening of the PTP
may initiate apoptosis in di¡erent cell systems. To
date, there is no data pertaining to mitochondrial
AIFs in human neurodegenerative diseases. The
role of cytoplasmic factors, such as NFU-B and
GAPDH, also remains to be delineated.
5.5. Oxidant stress and mitochondrial apoptosis
Mitochondrial dysfunction, with a fall in ATP
production, can be associated with an increase in
mitochondrially derived ROS [196,197]. Increased
levels of oxidative radicals, particularly in the pres-
ence of increased intramitochondrial Ca2, can in-
duce apoptosis by causing cross linking of protein
thiols in the mitochondrial inner membrane [198]
with opening of the PTP [170,199]. BCL-2 has been
shown to act as an anti-oxidant [176] and might pro-
vide anti-apoptotic e¡ects through this mechanism as
well as by its direct e¡ect on the PTP. A decrease in
BCL-2 levels in trophically deprived PC12 cells enter-
ing apoptosis is associated with markedly increased
cytosolic levels of oxidative radicals [200]. In con-
trast, the reduction in apoptosis induced by bcl-2
overexpression is associated with a decrease in both
ROS levels and in peroxidation of membrane lipids
[176]. Similar e¡ects have been detected with radical
scavengers, such as SOD-1 and glutathione, which
have been shown to prevent the direct action of ox-
idative radicals on PTP opening [170,199]. Thus, a
defect in mitochondrial respiratory chain activity, as
has been detected in PD and AD [135,137,201],
might lead to apoptosis through increased produc-
tion of oxidative radicals, as well as through de-
creased proton pumping with a fall in v8M and
opening of the PTP. These direct and indirect actions
on the PTP may reinforce each other in inducing
apoptosis. A more detailed explanation of the indi-
rect e¡ects of BCL-2 on cellular redox equilibrium is
provided in reference [202].
5.6. Mitochondria and apoptosis in neurodegenerative
disease
Mitochondria were not previously thought to con-
tribute to the initiation or progression of apoptosis.
Central to that viewpoint was the ¢nding that ¢bro-
blasts lacking mitochondrial DNA (mtDNA), b‡
cells, could die from apoptosis caused by staurospor-
ine treatment or trophic withdrawal, and that this
model of apoptosis could be blocked by bcl-2 over-
expression [150]. Although an absence of mtDNA in
b‡ cells compromises the synthesis of a number of
proteins necessary for mitochondrial ATP produc-
tion, it does not result in a loss of v8M or induce
apoptosis consequent to a fall in v8M. b‡ cells utilize
ATP produced from glycolysis to maintain v8M,
which decreases early in apoptosis caused by expo-
sure to TNF-K or to cycloheximide [165,203,204].
Indeed, high levels of Ca2 which reduce v8M, or
treatment with atractyloside which allows the release
of a soluble mitochondrial factor, have been shown
to induce the nuclear stigmata of apoptosis in a cell-
free system [204]. Thus, deletion of mtDNA does not
appear to impair the capacity of mitochondria to
maintain v8M or to develop apoptosis related to a
fall in v8M with release of mitochondrial AIFs.
We believe that apoptosis is an important form of
cell death in neurodegenerative disorders and that an
early decrease in v8M is one of the central hallmarks
of some forms of apoptosis, leading to opening of
the PTP and release of mitochondrial AIFs. This
hypothesis predicts that agents that lower v8M or
facilitate opening of the PTP promote apoptosis
while those that promote its closure are anti-apop-
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totic (see Fig. 1B,C). This theory explains why apop-
tosis is inhibited by agents, such as BCL-2 and cyclo-
sporin A, which maintain PTP closure [162] and
Ruthenium red, which block Ca2 entry into mito-
chondria [205,206]. Furthermore, this hypothesis of-
fers an explanation as to how ROS [207], mitochon-
drial complex I toxins like MPP [20,21], and
increased cytoplasmic Ca2 [208] can promote the
development of apoptosis and why increases in levels
of sod-1 and glutathione can inhibit the likelihood of
developing apoptosis [91,92,170]. Lastly, the theory
would explain why a reduction in v8M precedes pre-
and post-translational molecular events associated
with apoptosis, such as cytoskeletal depolymeriza-
tion, membrane blebbing and chromatin condensa-
tion with DNA strand cleavage.
At present, there is no direct evidence as to
whether a decrease in v8M contributes to human
neurodegenerative diseases. In pilot studies, we em-
ployed laser confocal microscopic techniques using
the potentiometric dye, CMTMR to measure v8M
in cutaneous ¢broblasts taken from PD patients and
age-matched controls (Chalmers-Redman, Olanow
and Tatton, unpublished observations). Image anal-
ysis revealed a signi¢cant loss of mitochondria with
high levels of v8M in PD ¢broblasts compared to
controls (Fig. 3). We hypothesize that the decrease
in v8M in PD ¢broblasts results from reduced pro-
ton pumping due to the reported complex I defect. A
shift in v8M to lower levels could render cells vul-
nerable to PTP opening and the initiation of apop-
tosis. Recently, neuroblastoma cells transfected with
a SOD-1 mutation that causes familial ALS have
been shown to have decreased v8M, similar to
what we observed in the PD ¢broblasts [209]. Ac-
cordingly, the decreases in mitochondrial complex
activity found in PD, AD, and HD may make neu-
rons vulnerable to apoptosis through a relative fail-
ure of proton pumping and a consequent decrease in
v8M.
6. Implications for therapy
Our current understanding suggests that apoptosis
is associated with a sequence of events in which mi-
tochondria are intimately involved. These include:
(a) a fall in v8M, coupled with a rise in intramito-
chondrial calcium; (b) opening of the mitochondrial
PTP; and (c) release of small mitochondrial proteins,
which signal the initiation of apoptosis. If a decrease
in v8M is, in fact, a characteristic feature of mito-
chondria in neurodegenerative disease then studies of
the complex I defect and apoptotic mechanisms in
the ¢broblasts and other a¡ected disease tissues
could serve to elucidate the pathogenesis of speci¢c
neurodegenerative diseases. Additionally, measure-
ments of v8M in peripheral tissues could o¡er an
early marker for one or more of the neurodegener-
ative diseases. A search for factors capable of induc-
ing apoptosis in tissues from persons with neurode-
generative diseases may aid in the recognition of the
agents and the mechanisms that initiate the diseases.
This schema also provides an opportunity to inter-
fere with the cell death process and to design puta-
tive neuroprotective therapy for patients with neuro-
degenerative diseases. Such an approach might
include agents which: (a) preserve the v8M ; (b)
maintain closure of the PTP; and (c) modify the
expression or the synthesis of apoptosis-related pro-
teins or, alternatively, that bind to apoptosis-related
proteins and change their shape or binding proper-
ties. Such approaches have the advantage of provid-
ing bene¢t regardless of the speci¢c etiologic or
pathogenic basis of neurodegeneration.
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